AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca PLC's (AZN) American depositary receipts (ADRs) fell more than 4% Thursday after the drug maker reported its profit was hurt by falling demand for COVID-19 treatments.

AstraZeneca Revenue Hurt as Demand for COVID-19 Treatments Slumps; Stock Drops

ConocoPhillips

Hershey

Philip Morris

We're once again reassured that employment, on a finer week-over-week scale, is not falling off a cliff.

Jobless Claims Steady; Mixed Q4 for AZN, HSY and PM

Loss of muscle mass also flagged, as UK drugmaker works with China's Eccogene on obesity and type 2 diabetes pill

Weight-loss drugs need to become cheaper, says AstraZeneca boss

AstraZeneca reported core earnings for the fourth quarter just short of consensus, but said it expected double-digit percentage growth in 2024.

AstraZeneca Earnings Hit By Higher Costs

AstraZeneca (AZN) marginally misses fourth-quarter estimates for earnings and sales. It expects revenues and EPS to increase at a low double-digit to low teens percentage in 2024 at CER.

AstraZeneca (AZN) Q4 Earnings & Sales Miss Estimates, Stock Down

Deutsche Bank also cut its rating of the stock to Sell from Buy.

AstraZeneca Slips as Earnings, Cancer Drug Sales Disappoint

AZN stock took a header early Thursday after a mixed Q4 report and a downgrade to sell on "thoroughly underwhelming" results.

AstraZeneca Downgraded On 'Underwhelming' Q4 Earnings

Catalent

Astrazeneca on Thursday said the sale of contract drugmaker Catalent to the parent of Novo Nordisk this week demonstrates the importance of building an independent supply chain.

Astrazeneca says Catalent deal shows importance of in-house capacity

AstraZeneca PLC (LSE:AZN) shares fell 1.8%, wiping £2.8 billion from the value of the business, as lingering concerns on the drug maker's cost base overshadowed better than expected results and strong forward guidance. Shore Capital is hoping management can dispell these worries: "We sense there had been an element of uncertainty heading into results around how quickly the cost base could continue to evolve over the near-medium term and expect some further clarity might be provided around this during the call today that could help to quell any concerns that might have been lingering.

AstraZeneca sees £2.8bn knocked off its value amid cost concerns

Strong growth and pipeline momentum with three new medicines approved since the third quarter.

AstraZeneca Full year and Q4 2023 Financial Results

Sophia Genetics SA

SOPHiA GENETICS and AstraZeneca Spain expand HRD testing program to support molecular diagnosis of ovarian cancer in Spain BOSTON and ROLLE, Switzerland and MADRID , Feb. 7, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it has expanded an existing program in Spain to increase access to local testing for homologous recombination deficiency (HRD) throughout the country. The expansion of the program, supported by AstraZeneca Spain and its network throughout the country, will further SOPHiA GENETICS' commitment to global health equity by making this vital testing available to thousands more patients in the country.

SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain

AstraZeneca said on Tuesday it will invest $300 million in a facility in Rockville, Maryland for discovery and development of cell therapies.

AstraZeneca to invest $300 million in US facility for cell therapies

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca is investing $300 million in a state-of-the-art facility in Rockville, MD to launch its life-saving cell therapy platforms in the US for critical cancer trials and future commercial supply. More than 150 new highly skilled jobs will be created to initially focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the world. Over time, the site may expand its focus to support other disease areas. The site represents th.

AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development

Eli Lilly

Artificial intelligence grabbed most of the headlines last year, but weight loss stocks were equally noteworthy. It grew slowly for several years but really went stratospheric last year.

NVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment?

AstraZeneca PLC (LSE:AZN) shares have continued their underperformance from the final quarter of last year into January, with Barclays identifying three major debates around the stock ahead of this week's results.  Since hitting an all-time high above £128 per share last April, the shares have fallen more than 19% and in the fourth quarter underperformed the Stoxx Europe 600 health sector by around 6%.

AstraZeneca facing three big investor debates as results loom, says Barclays

Evaluate the expected performance of Astrazeneca (AZN) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Astrazeneca (AZN) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates

Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.

AstraZeneca (AZN) to Report Q4 Earnings: Here's What to Expect

AstraZeneca is one of the fastest-growing pharmaceutical companies. On February 8, 2024, the company will publish financial results for the 4th quarter of 2023. From a broader perspective, AstraZeneca's EPS is expected to continue to grow through 2026.

AstraZeneca's Q4 Earnings: Recognizing The Underrated Gem's Growth

Wall Street doesn't have great expectations for the "Magnificent Seven" stocks in 2024. Analysts think that one big pharma stock could jump by more than 20% over the next 12 months.

History Says the Nasdaq Will Keep Soaring in 2024. Here's the Surprising Megacap Stock Wall Street Thinks Will Be the Biggest Winner.

AstraZeneca PLC (LSE:AZN) recently committed to reporting how its business impacts nature as part of annual corporate results, but next Thursday's final results are not likely to focus on anything other than operation and financial performance. The pharmaceutical giant lost its FTSE 100 number one spot to Shell last year (and regained it temporarily last month) but boss Pascal Soriot has been hard at work to wrestle back the crown for good in 2024, as well as dismissing rumours about an impending retirement.

AstraZeneca's mini acquisition spree comes as core oncology drugs face pressure

AstraZeneca's (AZN) sBLA for Enhertu to treat metastatic HER2-positive solid tumors gets priority review status by the FDA. A final decision is expected in second-quarter 2024.

AstraZeneca's (AZN) sBLA for Enhertu Gets FDA's Priority Tag

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

AstraZeneca appears to be an underrated growth stock. Regeneron Pharmaceuticals stands out as a perpetual market leader.

3 Magnificent Stocks to Buy and Hold Forever

In the latest trading session, Astrazeneca (AZN) closed at $67.02, marking a +0.63% move from the previous day.

Astrazeneca (AZN) Laps the Stock Market: Here's Why

Data from a late-stage shows that AstraZeneca's (AZN) cancer combination therapy reduces the risk of disease progression or death in certain liver cancer patients by 23%.

AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

News for AstraZeneca Stock (AZN)